Icaft Eye Drops

Icaft is an H1, H2 & H4 histamine receptor antagonist and inhibitor of the release of histamine from mast cells. The activation of H1 receptor causes itching & H4 receptor causes itching & inflammation. Histamine binding with H1 & H2 receptor causes redness and swelling. Icaft also inhibit the release of histamine from mast cell through limit the entry of Ca++ across the membrane as a result prevent degranulation. Icaft also stabilize tight junction protein (zonula occludin) of conjuctival epithelium that normally becomes disorganized following allergen exposure so that decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated.


Icaft is used for the prevention of itching associated with allergic conjunctivitis.

Icaft is also used to associated treatment for these conditions: Seasonal Allergic Conjunctivitis

Trade Name Icaft
Generic Alcaftadine
Other Names Alcaftadina, Alcaftadine, Alcaftadinum
Weight 0.25%
Type Eye Drops
Formula C19H21N3O
Weight Average: 307.3895
Monoisotopic: 307.168462309
Protein binding

The protein binding of alcaftadine and the active metabolite are 39.2% and 62.7% respectively.

Therapeutic Class Ophthalmic Anti-allergic preparations
Manufacturer Navana Pharmaceuticals Ltd
Available Country Bangladesh
Last Updated: June 23, 2021 at 11:16 am


Icaft dosage

Instill one drop in each eye once daily.

Side Effects

Reported side effects are irritation, burning, eye redness, itching etc. Other side effects are headache, ocular pruritus and nasopharyngitis.


The drug should not be instilled while wearing contact lenses. If hypersensitivity reaction occurs after instillation patients should be advised to discontinue the use of Icaft and consult with physicians.

Food Interaction

No interactions found.

Half Life

The elimination half-life of the carboxylic acid metabolite is approximately 2 hours following topical ocular administration.

Pregnancy & Breastfeeding use

Icaft is pregnancy Category B. Icaft has not been shown to cause birth defects or other problems during pregnancy and breastfeeding. It is not known whether Icaft is secreted in human milk or not. Caution should be exercised when Icaft is administered to a nursing mother.


It is contraindicated in persons with a known hypersensitivity to any component of this product.

Special Warning

Pediatric Use: Safety and effectiveness in pediatric patients below the age of 2 years have not been established. 

Geriatric Use: No overall differences in safety or effectiveness were observed between elderly and younger subjects.

Acute Overdose

Ocular Adverse Reactions: The most frequent ocular adverse reactions, occurring in <4% of alcaftadine eye drops treated eyes were eye irritation, burning and/or stinging upon instillation, eye redness and eye pruritus. 

Non-ocular Adverse Reactions: The most frequent non-ocular adverse reactions, occurring in <3% of subjects with alcaftadine eye drops treated eyes, were nasopharyngitis, headache and influenza. Some of these events were similar to the underlying disease being studied.

Interaction with other Medicine

No information is available.

Storage Condition

- Store in a cool, dry place and protected from light.

- Keep out of the reach of children.

- Discard the container 4 weeks after opening.

Icaft contains Alcaftadine see full prescribing information from innovator Monograph